Mwanzo6MK • FRA
add
Merck & Co.
Bei iliyotangulia
€ 101.80
Bei za siku
€ 101.60 - € 101.60
Bei za mwaka
€ 90.70 - € 125.00
Thamani ya kampuni katika soko
288.18B USD
Wastani wa hisa zilizouzwa
370.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NYSE
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 16.11B | 7.16% |
Matumizi ya uendeshaji wa biashara | 5.42B | 4.94% |
Mapato halisi | 5.46B | 191.30% |
Kiwango cha faida halisi | 33.86 | 185.20% |
Mapato kwa kila hisa | 2.28 | 210.68% |
EBITDA | 8.08B | 19.52% |
Asilimia ya kodi ya mapato | 9.07% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 11.35B | 78.02% |
Jumla ya mali | 112.63B | 7.81% |
Jumla ya dhima | 68.98B | 4.95% |
Jumla ya hisa | 43.65B | — |
hisa zilizosalia | 2.53B | — |
Uwiano wa bei na thamani | 5.92 | — |
Faida inayotokana na mali | 16.06% | — |
Faida inayotokana mtaji | 22.48% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 5.46B | 191.30% |
Pesa kutokana na shughuli | 5.64B | 52.19% |
Pesa kutokana na uwekezaji | -1.07B | 90.66% |
Pesa kutokana na ufadhili | 1.22B | -67.64% |
Mabadiliko halisi ya pesa taslimu | 5.70B | 239.96% |
Mtiririko huru wa pesa | 4.41B | 50.42% |
Kuhusu
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has multiple blockbuster drugs or products each with 2020 revenues including cancer immunotherapy, anti-diabetic medication and vaccines against HPV and chickenpox.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1 Jan 1891
Tovuti
Wafanyakazi
71,000
